文献速递类风湿关节炎脊柱关节炎

炎症性风湿病中生物制剂及靶向合成改善病情抗风湿药经济有效使用的考虑要点:伞形综述与国际德尔菲研究结果

Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
PubMed 文献 · RMD Open · 2023-01-01

该研究遵循EULAR程序,由来自7个欧洲国家的13名风湿病学、流行病学和药理学专家组成国际工作组,通过系统检索PubMed和Embase纳入30篇系统综述和21项随机对照试验,采用德尔菲法形成5条总体原则和20条考虑要点。20条中有10条(50%)获1级或2级证据支持,平均同意度(LoA)在7.9(1.2)至9.8(0.4)之间。

要点

  • 工作组就生物制剂及靶向合成改善病情抗风湿药(b/tsDMARDs)的经济有效使用达成5条总体原则。
  • 20条考虑要点覆盖应答预测、药品目录使用、生物类似药、负荷剂量、低剂量起始治疗等策略。
  • 20条考虑要点中有10条(50%)获1级或2级证据支持,平均LoA在7.9(1.2)至9.8(0.4)之间。

核心结论

  • 这些考虑要点可用于风湿病临床实践,并作为炎症性风湿病治疗指南的补充,以便在b/tsDMARD治疗中纳入成本效益考量。

研究设计与样本

  • 遵循EULAR程序,成立由来自7个欧洲国家的13名风湿病学、流行病学和药理学专家组成的国际工作组。
  • 通过个人和小组讨论确定12项b/tsDMARD经济有效使用策略,并针对每项策略系统检索PubMed和Embase中的英文系统综述,其中6项策略另检索随机对照试验。
  • 共纳入30篇系统综述和21项随机对照试验,工作组基于证据采用德尔菲法制定总体原则和考虑要点,并为每条考虑要点确定证据等级(1a-5)和推荐分级(A-D)。
  • 对同意度(LoA,0分为完全不同意,10分为完全同意)进行匿名个人投票。

主要发现

  • 工作组就5条总体原则达成一致。
  • 12项策略中有10项证据充分,可形成一条或多条考虑要点,共形成20条考虑要点。
  • 20条考虑要点涉及应答预测、药品目录使用、生物类似药、负荷剂量、低剂量起始治疗、联用传统合成改善病情抗风湿药、给药途径、用药依从性、疾病活动度指导的剂量优化和非医疗原因换药。
  • 20条考虑要点中有10条(50%)获1级或2级证据支持。
  • 平均LoA(SD)在7.9(1.2)至9.8(0.4)之间。

关键数值与推荐

  • 每条考虑要点的证据等级按1a-5评定,推荐分级按A-D评定。
  • 20条考虑要点中有10条(50%)获1级或2级证据支持。
  • 平均LoA(SD)在7.9(1.2)至9.8(0.4)之间,LoA范围为0分(完全不同意)至10分(完全同意)。

临床怎么用

  • 原文认为这些考虑要点可用于风湿病临床实践,并补充炎症性风湿病治疗指南,以便在b/tsDMARD治疗中纳入成本效益考量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To develop evidence-based points to consider for cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases, specifically rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. METHODS: Following EULAR procedures, an international task force was formed, consisting of 13 experts in rheumatology, epidemiology and pharmacology from seven European countries. Twelve strategies for cost-effective use of b/tsDMARDs were identified through individual and group discussion. For each strategy, PubMed and Embase were systematically searched for relevant English-language systematic reviews and, for six strategies, additionally for randomised controlled trials (RCTs). Thirty systematic reviews and 21 RCTs were included. Based on the evidence, a set of overarching principles and points to consider was formulated by the task force using a Delphi procedure. Level of evidence (1a-5) and grade (A-D) were determined for each point to consider. Individual voting on the level of agreement (LoA; between 0 (completely disagree) and 10 (completely agree)) was performed anonymously. RESULTS: The task force agreed on five overarching principles. For 10 of 12 strategies, the evidence was sufficient to formulate one or more points to consider, leading to 20 in total, regarding response prediction, drug formulary use, biosimilars, loading doses, low-dose initial therapy, concomitant conventional synthetic DMARD use, route of administration, medication adherence, disease activity-guided dose optimisation and non-medical drug switching. Ten points to consider (50%) were supported by level 1 or 2 evidence. The mean LoA (SD) varied between 7.9 (1.2) and 9.8 (0.4). CONCLUSION: These points to consider can be used in rheumatology practices and complement inflammatory rheumatic disease treatment guidelines to incorporate cost-effectiveness in b/tsDMARD treatment.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. van der Togt CJT, Van den Bemt B, Aletaha D, et al. Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study. RMD Open. 2023. PMID: 36863753. doi:10.1136/rmdopen-2022-002898

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。